Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

SciClone Pharma Enters $120 Million Deal for Two Neuroblastoma Treatments

publication date: Dec 18, 2020

SciClone Pharma, a US company that in-licenses novel antibody therapies for use in China, acquired rights for two neuroblastoma drugs from Y-mAbs of New York in a $120 million agreement. SciClone will pay $20 million upfront and as much as $100 million in milestones, plus royalties.  Danyelza® (naxitamab-gqgk) is a US-approved treatment for relapsed/refractory high-risk neuroblastoma. Omburtamab is being developed for pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021